Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer

Clinical Immunology

Volumn 128, Issue 2, 2008, Pages 205-218

  Dobrzanski, Mark J ^a   Reome, Joyce B ^b   Hylind, James C ^b   Rewers Felkins, Kathleen A ^a   Abulsamad, Khaliquzzaman ^a   Adams, Shawna L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TRUDEAU INSTITUTE   (United States)

Author keywords

Adoptive T cell transfer; Chemokines cytokines; Chemotherapy; Endogenous T effector cells; Host antitumor responses; Tc1 Th1 T cell subpopulations; Type 1 antitumor responses

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; METHOTREXATE;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL TRANSFER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, THY-1; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; METHOTREXATE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 46749092863     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.03.518     Document Type: Article

References (59)

1. Chabner B.A., and Roberts Jr. T.G. Chemotherapy and the war on cancer. Nat. Rev., Cancer 5 (2005) 65-72
2. Longley D.B., Harkin D.P., and Johnson P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev., Cancer 3 (2003) 330-338
3. Messman R.A., and Allegra C.J. In: Chabner B.A., and Longo D. (Eds). Cancer Chemotherapy and Biotherapy (2001), Lippincott Williams and Wilkins, Philadelphia, PA 139-184
4. Jolivet J., Cowan K.H., Curt G.A., Clendeninn N.J., and Chabner B.A. The pharmacological and clinical use of methotrexate. N. Engl. J. Med. 309 (1983) 1094-1104
5. Benz C., Tillis T., Tattelman E., and Cadman E. Optimal scheduling of methotrexate and 5-FU in human breast cancer. Cancer Res. 42 (1982) 2081-2086
6. Rosenberg S.A. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350 (2004) 1461-1465
7. Bishop M.R., Fowler D.H., Marchigiani D., Castro K., Kasten-Sportes C., Steinberg S.M., Gea-Banacloche J.C., Dean R., Chow C.H., Carter C., Read E.J., Leitman S., and Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J. Clin. Oncol. 22 (2004) 3886-3894
8. Yee C., Thompson J.A., Bryd D., Ridell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8 T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. 99 (2002) 16168-16176
9. Yee C., Thompson J.A., Roche P., Bryd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., and Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med., 192 (2000) 1637-1643
10. Dudley M.E., Wunderlich J.R., Robbins J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
11. Dudley M.E., and Rosenberg S.A. Adoptive T cell transfer therapy for the treatment of patients with cancer. Nat. Rev., Cancer 3 (2003) 666-675
12. North R.J. Downregulation of the antitumor immune response. Adv. Cancer Res. 45 (1985) 1-43
13. Singh S., Ross S.R., Acena M., Rowley D.A., and Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175 (1992) 139-146
14. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., and Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258 (1992) 1795-1798
15. Marincola F.M., Wang E., Herlyn M., Seliger B., and Ferrone S. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol. 24 (2003) 334-341
16. Jiang H., and Chess L. Regulation of immune responses by T cells. N. Engl. J. Med. 354 (2006) 1166-1176
17. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., and June C.H. Regulatory CD4CD25 T cells in tumors from patients with early stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res. 61 (2001) 4766-4774
18. Endharti A.T., Rifa'I M., Shi Z., Fukuoka Y., Nakahara Y., Kawamoto Y., Takeda K., Isobe K., and Suzuki H. Cutting Edge: CD8 CD122 regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8 T cells. J. Immunol. 175 (2005) 7093-7097
19. Chess L., and Jiang H. Resurrecting CD8 suppressor T cells. Nat. Immunol. 5 (2004) 469-471
20. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burrow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Luckner A., Disis M.L., Knutson K.L., Chen L., and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
21. Surh C.D., and Sprent J. Regulation of mature T cell homeostasis. Sem. Immunol. 17 (2005) 183-191
22. Almeida A.R.M., Rocha B., Freitas A.A., and Tanchot C. Homeostasis of T cell numbers: from thymus production to peripheral compartmentalization and the indexation of regulatory T cells. Sem. Immunol. 17 (2005) 239-249
23. Piccirillo C.A., and Shevach E.M. Naturally occurring CD4/CD25 immunoregulatory T cells: central players in the arena of peripheral tolerance. Sem. Immunol. 16 (2004) 81-88
24. Croft M., Carter L.L., Swain S.L., and Dutton R.W. Generation of polarized antigen specific CD8 effector populations: reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180 (1994) 1715-1794
25. Sad S.R., Marcotte R., and Mosmann T.R. Cytokine induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting th1 or th2 cytokines. Immunity 2 (1995) 271-280
26. Vukmanovic-Stejic M., Vyas B., Gorak-Stolinska P., Noble A., and Kemeny D.M. Human Tc1 and Tc2/Tc0 CD8 T cell clones display distinct cell surface and functional phenotypes. Blood 95 (2000) 231-237
27. Salgame P., Abrams J.S., Clayberger C., Goldstein H., Convit J., Modlin R.L., and Bloom B. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254 (1991) 279-283
28. Maggi E., Manetti R., Annunziato F., Cosmi L., Giudizi M.G., Biagiotti R., Galli G., Zuccati G., and Romagnani S. Functional characterization and modulation of cytokine production by CD8 T cells from human immunodeficiency virus-infected individuals. Blood 89 (1997) 3672-3679
29. Dobrzanski M.J., Reome J.B., Hollenbaugh J.A., and Dutton R.W. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J. Immunol. 172 (2004) 1380-1391
30. Dobrzanski M.J., Reome J.B., Hylind J.C., and Rewers-Felkins K.A. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation and function in progressive breast cancer. J. Immunol. 177 (2006) 8191-8201
31. Dobrzanski M.J., Reome J.B., Hollenbaugh J.A., Hylind J.C., and Dutton R.W. Effector cell-derived lymphotoxin-α and FasL, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res. 64 (2004) 406-413
32. Morgan J.D., Liblau R., Scott B., Fleck S., McDevitt H.O., Sarvetnick N., Lo D., and Sherman L.A. CD8 T cell mediated spontaneous diabetes in neonatal mice. J. Immunol. 157 (1996) 978-986
33. Nanni P., de Giovanni C., Lollini P.L., and Prodi G. TS/A: a new metastasizing cell line from BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 4 (1983) 373-380
34. Cerwenka A., Morgan T.M., and Dutton R.W. Naïve, effector and memory CD8 T cells in protection against pulmonary influenza virus infection: Homing properties rather than initial frequencies are crucial. J. Immunol. 163 (1999) 5535-5543
35. Lawrence C.W., and Braciale T.J. Activation, differentiation and migration of naïve virus-specific CD8 T cells during pulmonary influenza virus infection. J. Immunol. 173 (2004) 1209-1218
36. Lake R.A., and Robinson B.W.S. Immunotherapy and chemotherapy - a practical partnership. Nat. Rev., Cancer 5 (2005) 397-405
37. Awwad M., and North R.J. Cyclophosphamide (CY)-facilitated adoptive immunotherapy of a CY-resistant tumor. Evidence that CY permits the expression of adoptive T cell-mediated immunity by removing suppressor T cells rather than by reducing tumor burden. Immunology 65 (1988) 87-92
38. Taieb J., Chaput N., Schartz N., Roux S., Novault S., Menard C., Ghiringhelli F., Terme M., Carpentier A.F., Darrasse-Jese G., Lemonnier F., and Zitvogel L. Chemotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176 (2006) 2722-2729
39. Nowak A.K., Robinson B.W.S., and Lake R.A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63 (2003) 4490-4496
40. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumors. Nat. Rev., Cancer 6 (2006) 583-592
41. Luster A.D. Chemokines: chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338 (1998) 436-445
42. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., Baggiolini M., and Moser B. Chemokine receptor specific for IP-10 and MIG: structure, function and expression in activated T lymphocytes. J. Exp. Med. 184 (1996) 963-969
43. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
44. Homey B., Muller A., and Zlotnik A. Chemokines: agents for immunotherapy of cancer. Nat. Rev., Immunol. 2 (2002) 175-187
45. Siveke J.T., and Hamann A. Cutting Edge: T helper 1 and T helper 2 cells respond differentially to chemokines. J. Immunol. 160 (1998) 550-554
46. Poznansky M.C., Olszak I.T., Foxall R., Evans R.H., Luster A.D., and Scadden D.T. Active movement of T cells away from a chemokine. Nat. Med. 6 (2000) 543-548
47. Hodge D.L., Schill W.B., Wang J.M., Blanca I., Reynolds D.A., Ortaldo J.R., and Young H.A. IL-2 and IL-12 alter NK cell responsiveness to IFN-γ-inducible protein 10 by down regulating CXCR3 expression. J. Immunol. 168 (2002) 6090-6098
48. Rosenberg S.A., Spiess P., and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233 (1986) 1318-1321
49. Restifo N.P. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol. 12 (2000) 597-603
50. Shi Y., Evans J.E., and Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521
51. Micheau O., Solary E., Hammann A., Martin F., and Dimanche-Boitrel M.T. Sensitization of cancer cells treated with cytoablative drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst. 89 (1997) 783-786
52. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev., Cancer 6 (2006) 24-37
53. Bisikirska B., Colgan J., Luban J., Bluestone J.A., and Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8 T cell populations and induce CD8 CD25 Tregs. J. Clin. Invest. 115 (2005) 2904-2913
54. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFN-γ and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 410 (2001) 1107-1111
55. Dobrzanski M.J., Reome J.B., and Dutton R.W. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98 (2001) 70-81
56. Shrikant P., and Mescher M.F. Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J. Immunol. 169 (2002) 1753-1759
57. Antony P.A., Paulos C.M., Ahmadzadeh M., Akpinarli A., Palmer D.C., Sato N., Kaiser A., Heinrichs C., Klebanoff C.A., Tagaya Y., and Restifo N.P. IL-2-dependent mechanisms of tolerance and immunity in vivo. J. Immunol. 176 (2006) 5255-5266
58. Giovarelli M., Cappello P., Forni G., Salcedo T., Moore P.A., LeFleur D.W., Nardelli B., Di Carlo E., Lollini P., Ruben S., Ullrich S., Garotta G., and Musiani P. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes and granulocytes. J. Immunol. 164 (2000) 3200-3212
59. Pan J., Burdick M.D., Belperio J.A., Xue Y.Y., Gerard C., Sharma S., Dubinett S.M., and Strieter R.M. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J. Immunol. 176 (2006) 1456-1464